TO THE EDITOR: I would like to thank Dr. Davidoff for his editorial on drug pricing (1) . The ends to which pharmaceutical companies will go to achieve ever-greater profits are astonishing. I recently received from Amgen (Thousand Oaks, California) an announcement of another price increase in their product Epogen (erythropoietin). Amgen rationalized this increase by saying that it had not raised prices in several years and that it was merely following the consumer price index. In a recent issue, The Medical Letter noted that Amgen has been using direct-to-consumer advertising for Epogen. There is also a black market for Epogen among athletes.
Epogen is required for good-quality care of patients receiving dialysis and many patients receiving chemotherapy. The indications have expanded to include predialysis patients. Clearly, there is no real competition among the licensed manufacturers of this agent. At the same time, neither the users nor the prescribers are "consumers" as defined by the Consumer Price Index for Urban Consumers. I agree with Dr. Reinhardt's suggestion of establishing an impartial agency to evaluate the grossly exaggerated and disingenuous advertising claims made by pharmaceutical companies to both physicians and patients. One example of such claims was seen in San Francisco, California, where misleading billboard advertisements for antiretroviral agents were removed because HIV activists protested the unrealistic depictions of robust "consumers." An impartial agency would raise the standards for advertising and for determinations of efficacy. The U.S. Food and Drug Administration (FDA) once played this role. However, it has been emasculated as part of a well-intentioned effort to get life-saving drugs to patients quickly.
I hope editorials like Dr. Davidoff 's receive wide play in Washington, D.C.
Wes Lisker, MD
Hayward, CA 94545 IN RESPONSE: As Dr. Ross notes, companies do, of course, have a fiduciary obligation to their stockholders, but my editorial was intended to appeal to forces in corporate life other than purely fiscal ones. In fact, many pharmaceutical companies, as well as those in other sectors of the economy, take seriously their nonfinancial obligations, including those to their customers and other parts of the community, not just because it's the "right thing" to do but because it makes good, hard business sense. A well-known example is Johnson & Johnson's credo, which begins: "We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services" (1). This policy is widely credited with helping the company make good business decisions during the so-called Tylenol crisis (2) , which suggests that it is more than just window dressing.
The number of prescriptions written is, to be sure, driven primarily by doctors' willingness to write them. But lower drug prices could very well encourage doctors to write prescriptions, to their patients' benefit, in just those discretionary situations where they now hold back because they know patients would have trouble paying for them. Moreover, because of high costs, patients frequently fail to fill, or refill, prescriptions that could do them good. On this account as well, lower prices would almost certainly increase the actual volume of drug sales.
I agree totally with Dr. Ross about the need for universal health care, as I've stated previously (3) . The College is also on record as supporting universal access.
Dr. Lisker provides a number of important insights on drug sales and promotion, including the role of the FDA. The cost of FDA approval clearly influences drug prices, but the degree to which it does so is a complex subject. It does seem, however, that the current system, in which manufacturers' fees help pay for drug approval, muddies the regulatory waters, since it potentially provides industry with a kind of leverage that may not always be in the public's best interest.
Frank Davidoff, MD Editor Emeritus

Molecular Genetic Evidence of an Association between Nasal Polyposis and the Peutz-Jeghers Syndrome
TO THE EDITOR: The Peutz-Jeghers syndrome is an autosomal dominant disorder characterized by hamartomatous polyposis of the gastrointestinal tract, melanin pigmentation of the skin and mucous membranes, and an increased risk for cancer (1, 2) . It is caused by a germline mutation in the STK11/LKB1 gene on chromosome 19p13.3 (2). Hamartomas and carcinomas in patients with the Peutz-Jeghers syndrome show loss of heterozygosity at chromosome 19p13.3, indicating inactivation of the wild-type STK11/LKB1 gene (3). Peutz described the first family with the Peutz-Jeghers syndrome as having "a highly remarkable combination of polyposis of the mucosa of the intestinal tract and of the nasopharynx, together with typical mucocutaneous pigmentations" (1). Although nasal polyposis in affected patients has been mentioned occasionally (4, 5) , it is not a recognized extraintestinal manifestation of the disease. Consequently, we used a molecular genetic approach to investigate the association between nasal polyposis, the Peutz-Jeghers syndrome, and STK11/LKB1.
We studied 4 patients with the Peutz-Jeghers syndrome who came from 3 families with known germline mutations in STK11. Twelve nasal polyps from these 4 patients were available for study. We also analyzed 28 sporadic nasal polyps from 28 controls without evidence of the Peutz-Jeghers syndrome, the Kartagener syndrome, cystic fibrosis, or aspirin sensitivity. Polyp DNA was isolated from microdissected polyp epithelium, and wild-type DNA was isolated from stromal inflammatory cells. Loss of heterozygosity was assessed by comparing polyp DNA with normal DNA, as described elsewhere (3 In two unrelated patients with the Peutz-Jeghers syndrome, four of eight nasal polyps showed loss of heterozygosity at 19p13.3. In contrast, loss of heterozygosity was not found in 23 sporadic nasal polyps (P ϭ 0.002). Haplotype analysis showed that loss of heterozygosity comprised deletion of the wild-type allele (Figure) . Our findings indicate that nasal polyps related to the Peutz-Jeghers syndrome lack the functional STK11/LKB1 tumor-suppressor gene, suggesting a causal relationship between nasal polyp development and the Peutz-Jeghers syndrome. Loss of heterozygosity at 19p13.3 in nasal polyps of affected patients corresponds with reports of loss of heterozygosity in gastrointestinal hamartomatous polyps (3). Loss of heterozygosity at the STK11/LKB1 locus in nasal polyps related to the Peutz-Jeghers syndrome suggests that these lesions may be neoplastic in nature. This may also be reflected by the co-occurrence of nasal polyposis and nasopharyngeal squamous-cell carcinoma in a patient with the Peutz-Jeghers syndrome (4). We provide molecular genetic support for the initial observation of Dr. Peutz: Nasal polyposis can be an extraintestinal manifestation of the Peutz-Jeghers syndrome.
